Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
Purpose. Multidrug resistance (MDR) is a major obstacle in chemotherapy of leukemia treatments. In this paper, we investigated Usnea Acid (UA) as MDR reversal agent on hematologic K562/ADR cells via ROS dependent apoptosis. Methods. CCK8 assay was used to measure cell viability rate of K562/ADR. Int...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2019/8727935 |
id |
doaj-177dee0ff5c145c19975eda7ae0c3c92 |
---|---|
record_format |
Article |
spelling |
doaj-177dee0ff5c145c19975eda7ae0c3c922020-11-24T21:59:19ZengHindawi LimitedBioMed Research International2314-61332314-61412019-01-01201910.1155/2019/87279358727935Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent ApoptosisWenjing Wang0Shubin Niu1Luxin Qiao2Feili Wei3Jiming Yin4Shanshan Wang5Yabo Ouyang6Dexi Chen7Capital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaSchool of biomedicine, Beijing City University, No. 6 Huanghoudian Road Haidian District, Beijing, 100094, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaPurpose. Multidrug resistance (MDR) is a major obstacle in chemotherapy of leukemia treatments. In this paper, we investigated Usnea Acid (UA) as MDR reversal agent on hematologic K562/ADR cells via ROS dependent apoptosis. Methods. CCK8 assay was used to measure cell viability rate of K562/ADR. Intracellular reactive oxygen species (ROS) generation, cell cycle distribution, cell apoptosis were measured with flow cytometry, respectively. Proteins related to apoptosis were measured by Western blot. Intracellular Adriamycin accumulation was observed by confocal microscopy and measured by flow cytometry. Results. In vitro study showed intracellular Adriamycin accumulation was remarkably increased by UA. Cell viability treated with Adr (4 μM) was decreased from 89.8% ± 4.7 to 32% ± 8.9 by combined with UA (4 μM). Adr-induced apoptosis and G1/G0 phase cell cycle arrest were remarkably increased by UA, as well as, intracellular ROS level. However, MDR reversing activity of UA was inhibited by N-acetyl cysteine (NAC), a ROS scavenger. Conclusion. These data provide compelling evidence that UA is a promising agent against MDR in leukemia cell line and suggest a promising therapeutic approach for leukemia.http://dx.doi.org/10.1155/2019/8727935 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wenjing Wang Shubin Niu Luxin Qiao Feili Wei Jiming Yin Shanshan Wang Yabo Ouyang Dexi Chen |
spellingShingle |
Wenjing Wang Shubin Niu Luxin Qiao Feili Wei Jiming Yin Shanshan Wang Yabo Ouyang Dexi Chen Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis BioMed Research International |
author_facet |
Wenjing Wang Shubin Niu Luxin Qiao Feili Wei Jiming Yin Shanshan Wang Yabo Ouyang Dexi Chen |
author_sort |
Wenjing Wang |
title |
Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis |
title_short |
Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis |
title_full |
Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis |
title_fullStr |
Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis |
title_full_unstemmed |
Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis |
title_sort |
usnea acid as multidrug resistance (mdr) reversing agent against human chronic myelogenous leukemia k562/adr cells via an ros dependent apoptosis |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2019-01-01 |
description |
Purpose. Multidrug resistance (MDR) is a major obstacle in chemotherapy of leukemia treatments. In this paper, we investigated Usnea Acid (UA) as MDR reversal agent on hematologic K562/ADR cells via ROS dependent apoptosis. Methods. CCK8 assay was used to measure cell viability rate of K562/ADR. Intracellular reactive oxygen species (ROS) generation, cell cycle distribution, cell apoptosis were measured with flow cytometry, respectively. Proteins related to apoptosis were measured by Western blot. Intracellular Adriamycin accumulation was observed by confocal microscopy and measured by flow cytometry. Results. In vitro study showed intracellular Adriamycin accumulation was remarkably increased by UA. Cell viability treated with Adr (4 μM) was decreased from 89.8% ± 4.7 to 32% ± 8.9 by combined with UA (4 μM). Adr-induced apoptosis and G1/G0 phase cell cycle arrest were remarkably increased by UA, as well as, intracellular ROS level. However, MDR reversing activity of UA was inhibited by N-acetyl cysteine (NAC), a ROS scavenger. Conclusion. These data provide compelling evidence that UA is a promising agent against MDR in leukemia cell line and suggest a promising therapeutic approach for leukemia. |
url |
http://dx.doi.org/10.1155/2019/8727935 |
work_keys_str_mv |
AT wenjingwang usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis AT shubinniu usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis AT luxinqiao usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis AT feiliwei usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis AT jimingyin usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis AT shanshanwang usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis AT yaboouyang usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis AT dexichen usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis |
_version_ |
1725847799941038080 |